Topic Review
Psilocybin
Psilocybin, a psychoactive alkaloid contained in hallucinogenic mushrooms, is nowadays given a lot of attention in the scientific community as a research tool for modeling psychosis as well as due to its potential therapeutic effects. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research, rising in popularity during the 1960s and classified as a Schedule I drug in 1970. Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. 
  • 968
  • 23 Sep 2020
Topic Review
Post-Traumatic Stress Disorder in Caregivers
Post-traumatic stress disorder (PTSD) is a mental disorder typically occurring after the exposure, both direct and indirect, to a traumatic event, and is characterized by the onset and persistence of a series of clinical symptoms that can often be profoundly incapacitating and tendentially chronic. In the past decades, increasing attention has been deserved to PTSD among caregivers of patients affected by severe medical conditions characterized by a risk for life, a severe impairment or a chronic course (e.g. cancer, severe injuries, type 1 diabetes and neurologic disorders) highlighting the potential traumatic role of such experiences.
  • 970
  • 22 Sep 2020
Topic Review
Post-Traumatic Stress Disorder and Thalamus
Post-traumatic stress disorder is a common mental disorder, with high lifetime prevalence approximately 6–10% . The prevalence of PTSD in trauma-exposed people has been approximately 20%. PTSD is induced by traumatic stress including life threatening, actual or threatened severe injury, and sexual violence. In DSM-V criteria, PTSD has the following symptoms: intrusion of unwanted memory updates related to traumatic stress, avoidance for reminders, negative alterations in mood, and hyper-arousal. Conservatively, fear-conditioned learning involving the amygdala has been considered one of the causative factors.
  • 1.3K
  • 03 Mar 2021
Topic Review
Physician Burnout in COVID-19 Period
The main aim of this study was to analyse and summarise the current knowledge on factors/potential factors contributing to burnout amongst healthcare professionals amidst the pandemic . This study also makes a few recommendations on how best to prepare intervention programmes for physicians. Results from our systematic review generally showed that the introduction of COVID-19 has heightened existing challenges that physicians face such as increasing workload, which is directly correlated with increased burnout. However, exposure to COVID-19 does not necessarily correlate with increased burnout and is an area for more research. There is some evidence showing that techniques such as mindfulness may help relieve burnout. However, given the small number of studies focusing on physician burnout amidst a pandemic, conclusions should be taken with caution. More studies are needed to support these findings.
  • 534
  • 09 Nov 2020
Topic Review
Pharmacogenomic Biomarkers in Psychiatry
Pharmacogenomic biomarkers are potential individual genetic variations that can affect drug response influencing both pharmacokinetic parameters by causing variable activity of the systems responsible for the absorption, distribution, metabolism, and excretion of the drug and pharmacodynamic parameters like the mechanisms of action of the drug. Here, the term "pharmacogenomic biomarkers in psychiatry" means those related to a variety of psychiatric disorders, such as depression, ADHD, narcolepsy, schizophrenia, bipolar disorder, and epilepsy. 
  • 657
  • 10 Feb 2021
Topic Review
Personality Neuroscience
It has long been understood that a multitude of biological systems, from genetics, to brain networks, to psychological factors, all play a role in personality. Understanding how these systems interact with each other to form both relatively stable patterns of behaviour, cognition and emotion, but also vast individual differences and psychiatric disorders, however, requires new methodological insight. Novel data-driven approaches, such as multilayer networks, may prove to be viable methods for explaining and predicting individual difference with greater veracity through incorporating data at more than one scale. 
  • 767
  • 15 Dec 2020
Topic Review
Paraphilia
Paraphilia (previously known as sexual perversion and sexual deviation) is the experience of intense sexual arousal to atypical objects, situations, fantasies, behaviors, or individuals. There is no scientific consensus for any precise border between unusual sexual interests and paraphilic ones. There is debate over which, if any, of the paraphilias should be listed in diagnostic manuals, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD). The number and taxonomy of paraphilia is under debate; one source lists as many as 549 types of paraphilia. The DSM-5 has specific listings for eight paraphilic disorders. Several sub-classifications of the paraphilias have been proposed, and some argue that a fully dimensional, spectrum or complaint-oriented approach would better reflect the evidence.
  • 1.4K
  • 29 Nov 2022
Topic Review
Noninvasive Vagal Nerve Stimulation
Neuromodulation is a promising new area with treatment applications for psychiatry. Electrical stimulation of the vagus nerve is associated with a reduction in peripheral sympathetic and inflammatory function and modulation of brain areas mediating fear and the stress response, and thus has potential applications to patients with stress-related psychiatric disorders, including posttraumatic stress disorder (PTSD) and depression. Non-invasive Vagal Nerve Stimulation (nVNS) can be applied to vagus nerve locations at the neck (transcutaneous cervical, or tcVNS) or ear (transcutaneous auricular, or taVNS), intervening at the level of the underlying psychobiology with potential beneficial treatment effects.   
  • 771
  • 18 Sep 2020
Topic Review
Modulation of Brain Hyperexcitability
People with Alzheimer’s disease (AD) have significantly higher rates of subclinical and overt epileptiform activity. In animal models, oligomeric Aβ amyloid is able to induce neuronal hyperexcitability even in the early phases of the disease. Such aberrant activity subsequently leads to downstream accumulation of toxic proteins, and ultimately to further neurodegeneration and neuronal silencing mediated by concomitant tau accumulation. Several neurotransmitters participate in the initial hyperexcitable state, with increased synaptic glutamatergic tone and decreased GABAergic inhibition. These changes appear to activate excitotoxic pathways and, ultimately, cause reduced long-term potentiation, increased long-term depression, and increased GABAergic inhibitory remodelling at the network level. Brain hyperexcitability has therefore been identified as a potential target for therapeutic interventions aimed at enhancing cognition, and, possibly, disease modification in the longer term. Clinical trials are ongoing to evaluate the potential efficacy in targeting hyperexcitability in AD, with levetiracetam showing some encouraging effects. Newer compounds and techniques, such as gene editing via viral vectors or brain stimulation, also show promise. Diagnostic challenges include identifying best biomarkers for measuring sub-clinical epileptiform discharges. Determining the timing of any intervention is critical and future trials will need to carefully stratify participants with respect to the phase of disease pathology.
  • 876
  • 24 Dec 2020
Topic Review
Mindfulness-Based Interventions for Schizophrenia
Mindfulness-based interventions (MBIs) consist of short and structured intervention protocols focused on teaching patients the use of mindfulness for therapeutic purposes. Over the last three decades, there has been a remarkable expansion of this kind of interventions for the treatment of various psychopathological conditions. Despite this, MBIs have only recently begun to be applied in the treatment of people with schizophrenia. Analysis of the available evidence on MBIs for the treatment of people with this disorder suggests that they are effective and safe treatments, although more research is needed to draw more robust conclusions.  
  • 1.1K
  • 13 Jul 2020
  • Page
  • of
  • 6